iwMyeloma 2022 | Day 2 wrap-up: pushing myeloma boundaries
Gareth Morgan, Keith Stewart, Leif Bergsagel and Rafael Fonseca
• 27 Mar 2022
Gareth Morgan, MD, PhD, FRCP, FRCPath, of NYU Langone Medical Center, New York, NY chairs this session with Rafael Fonseca, MD, of Mayo Clinic, Phoenix, AZ, Leif Bergsagel, MD, of Mayo Clinic, Phoenix, AZ, and Keith Stewart, MB, ChB, of Princess Margaret Cancer Centre, Toronto, Canada. The experts discuss the biology behind the use of BCL2 inhibitors such as venetoclax, T-cell exhaustion as a key cause of resistance in many immunotherapies, protein-degrading drugs, and also how patient outcomes are likely to be improved in the coming years. This discussion took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.
